MiR‐766‐3p Inhibit the Proliferation, Stemness, and Cell Cycle of Pancreatic Cancer Cells Through the MAPK/ERK Signaling Pathway
2024

MiR‐766‐3p Inhibits Pancreatic Cancer Cell Growth

Sample size: 100 publication 10 minutes Evidence: high

Author Information

Author(s): Zhipeng Quan, Ziwei Yin, Yuelin Huang, Xuemei Huang, Hao Huang, Qingrong Mo, Jianhua Gong, Lingyun Liu, Yi Zhou, Yaqun Yu

Primary Institution: Affiliated Hospital of Guilin Medical University

Hypothesis

MIR‐766‐3P expression is associated with pancreatic cancer development and progression.

Conclusion

MIR‐766‐3P inhibits pancreatic cancer cell proliferation and stemness by targeting MAPK1 and regulating the MAPK/ERK pathway.

Supporting Evidence

  • MIR‐766‐3P expression was significantly lower in pancreatic cancer tissues compared to normal tissues.
  • High levels of MIR‐766‐3P were associated with better prognostic outcomes in pancreatic cancer patients.
  • MIR‐766‐3P overexpression inhibited pancreatic cancer cell growth and stemness.
  • MIR‐766‐3P directly targets MAPK1, affecting the MAPK/ERK signaling pathway.
  • MAPK1 expression was found to be negatively correlated with MIR‐766‐3P levels in pancreatic cancer tissues.
  • Animal studies showed that MIR‐766‐3P mimics reduced tumor growth in vivo.

Takeaway

MIR‐766‐3P is like a superhero for pancreatic cancer cells, helping to stop them from growing and spreading.

Methodology

The study used miRNA RT‐PCR, western blot, qRT‐PCR, gain/loss-of-function assays, RNA sequencing, and luciferase reporter assays.

Participant Demographics

50 pancreatic cancer patients and 50 matched adjacent tissue samples.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/mgg3.70049

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication